Interaction of Pten gene and AKT/mTOR pathway in endometrial adenocarcinoma proliferation

Objective: The Pten/AKT/mTOR pathway is one of the most critical pathways in tumor proliferation. The present research aimed to analyze the interaction between Pten gene and AKT/mTOR pathway in endometrial cancer cell lines. Methods: TCGA analysis was used to study the relationship between Pten expression and survival of endometrial cancer patients. Human endometrial cancer cell lines with low Pten expression (Ishikawa) and with high Pten expression (HEC-1-A) were selected. Plasmid transfection was used to regulate the Pten expression in the cell lines. QRT-PCR and Western Blot were adopted to detect Pten/AKT/mTOR expressions in tumor cells. Western blot of Ki-67 and CCK-8 were adopted to detect the activity of cells proliferation. A p < 0.05 was considered to be statistically significant. Results: The TCGA analysis showed the Pten expression was associated with survival of endometrial cancer patients significantly. Plasmid transfections elevated Pten expression in Ishikawa and decreased Pten expression in HEC-1-A cells. After the plasmid transfection, with overexpression of Pten in Ishikawa cell line, the Western Blot and QRT-PCR revealed the AKT/mTOR pathway is restrained, leading to decreased cell proliferation; with Pten decreased in HEC-1-A cells, the AKT/mTOR pathway is activated, leading to increased cell proliferation. Conclusions: A decreased expression of Pten gene in Ishikawa and HEC-1-A cell lines could activate AKT/mTOR pathway and promote tumor cells proliferation.

Pten/AKT/mTOR pathway; endometrial cancer; tumor proliferation

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: a Cancer Journal for Clinicians. 2020; 70: 7–30.

[2] Saso S, Chatterjee J, Georgiou E, Ditri AM, Smith JR, Ghaem-Maghami S. Endometrial cancer. British Medical Journal. 2011; 343: d3954.

[3] Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecologic Oncology. 1983; 15: 10–17.

[4] Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C, et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2011; 24 Suppl 6: vi33–vi38.

[5] Chaudhry P, Asselin E. Resistance to chemotherapy and hormone therapy in endometrial cancer. Endocrine-Related Cancer. 2009; 16: 363–380.

[6] Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997; 275: 1943–1947.

[7] Luongo F, Colonna F, Calapà F, Vitale S, Fiori ME, De Maria R. PTEN Tumor-Suppressor: the Dam of Stemness in Cancer. Cancers. 2019; 11: 1076.

[8] Khemlina G, Ikeda S, Kurzrock R. The biology of Hepatocellular carcinoma: implications for genomic and immune therapies. Molecular Cancer. 2018; 16: 149.

[9] Papadimitrakopoulou V, Adjei AA. The AKT/mTOR and mitogen-activated protein kinase pathways in lung cancer therapy. Journal of Thoracic Oncology. 2006; 1: 749–751.

[10] Cai C, Dang W, Liu S, Huang L, Li Y, Li G, et al. Anthrax toxin receptor 1/tumor endothelial marker 8 promotes gastric cancer progression through activation of the PI3K/AKT/mTOR signaling pathway. Cancer Science. 2020; 111: 1132–1145.

[11] du Rusquec P, Blonz C, Frenel JS, Campone M. Targeting the PI3K/AKT/mTOR pathway in estrogen-receptor positive her2 negative advanced breast cancer. Therapeutic Advances in Medical Oncology. 2020; 12: 175883592094093.

[12] Wu Y, Zhu H, Wu H. PTEN in Regulating Hematopoiesis and Leukemogenesis. Cold Spring Harbor Perspectives in Medicine. 2020; 10: a036244.

[13] Chen J, Zhao K, Li R, Shao R, Chen C. Activation of PI3K/AKT/mTOR pathway and dual inhibitors of PI3K and mTOR in endometrial cancer. Current Medicinal Chemistry. 2014; 21: 3070–3080.

[14] Gabriel K, Ingram A, Austin R, Kapoor A, Tang D, Majeed F, et al. Regulation of the tumor suppressor PTEN through exosomes: a diagnostic potential for prostate cancer. PLoS ONE. 2013; 8: e70047.

[15] Zeng X, Hu Z, Ke X, Tang H, Wu B, Wei X, et al. Long noncoding RNA DLX6-as1 promotes renal cell carcinoma progression via miR-26a/PTEN axis. Cell Cycle. 2017; 16: 2212–2219.

[16] Jamaspishvili T, Berman DM, Ross AE, Scher HI, De Marzo AM, Squire JA, et al. Clinical implications of PTEN loss in prostate cancer. Nature Reviews. Urology. 2018; 15: 222–234.

[17] Osei-Amponsa V, Buckwalter JM, Shuman L, Zheng Z, Yamashita H, Walter V, et al. Hypermethylation of FOXA1 and allelic loss of PTEN drive squamous differentiation and promote heterogeneity in bladder cancer. Oncogene. 2020; 39: 1302–1317.

[18] Yu M, Trobridge P, Wang Y, Kanngurn S, Morris SM, Knoblaugh S, et al. Inactivation of TGF-β signaling and loss of PTEN cooperate to induce colon cancer in vivo. Oncogene. 2014; 33: 1538–1547.

[19] Hsu Y, Hung J, Chang W, Jian S, Lin Y, Pan Y, et al. Hypoxic Lung-Cancer-Derived Extracellular Vesicle MicroRNA-103a Increases the Oncogenic Effects of Macrophages by Targeting PTEN. Molecular Therapy. 2018; 26: 568–581.

[20] Sato N, Tsunoda H, Nishida M, Morishita Y, Takimoto Y, Kubo T, et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Research. 2000; 60: 7052–7056.

[21] Podsypanina K, Lee RT, Politis C, Hennessy I, Crane A, Puc J, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in PTEN+/-mice. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98: 10320–10325.

[22] Wang S, Zheng Y, He Z, Zhou W, Cheng Y, Zhang C. SH2B1 promotes NSCLC cell proliferation through PI3K/AKT/mTOR signaling cascade. Cancer Cell International. 2019; 18: 132.

[23] Kurgan N, Tsakiridis E, Kouvelioti R, Moore J, Klentrou P, Tsiani E. Inhibition of Human Lung Cancer Cell Proliferation and Survival by Post-Exercise Serum is Associated with the Inhibition of AKT, mTOR, p70 S6K, and Erk1/2. Cancers. 2017; 9: 46.

[24] Wu M, Yiang G, Cheng P, Chu P, Li C. Molecular Targets in Hepatocarcinogenesis and Implications for Therapy. Journal of Clinical Medicine. 2018; 7: 213.

[25] Mabuchi S, Kuroda H, Takahashi R, Sasano T. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. Gynecologic Oncology. 2015; 137: 173–179.

[26] Cheng JQ, Lindsley CW, Cheng GZ, Yang H, Nicosia SV. The AKT/PKB pathway: molecular target for cancer drug discovery.Oncogene. 2005; 24: 7482–7492.

[27] Lee Y, Chen M, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor: new modes and prospects. Nature Reviews. Molecular Cell Biology. 2018; 19: 547–562.

[28] Shoji K, Oda K, Nakagawa S, Hosokawa S, Nagae G, Uehara Y, et al. The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas. British Journal of Cancer. 2009; 101: 145–148.

[29] Caserta E, Egriboz O, Wang H, Martin C, Koivisto C, Pecót T, et al. Noncatalytic PTEN missense mutation predisposes to organ-selective cancer development in vivo. Genes & Development. 2015; 29: 1707–1720.

[30] Aquila S, Santoro M, Caputo A, Panno ML, Pezzi V, De Amicis F. The Tumor Suppressor PTEN as Molecular Switch Node Regulating Cell Metabolism and Autophagy: Implications in Immune System and Tumor Microenvironment. Cells. 2020; 9: 1725.

[31] Huang K, Fingar DC. Growing knowledge of the mTOR signaling network. Seminars in Cell & Developmental Biology. 2014; 36: 79–90.

[32] Ruicci KM, Plantinga P, Pinto N, Khan MI, Stecho W, Dhaliwal SS, et al. Disruption of the Rictor/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition. Molecular Oncology. 2019; 13: 2160–2177.

[33] Pantuck AJ, Seligson DB, Klatte T, Yu H, Leppert JT, Moore L, et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer. 2007; 109: 2257–2267.

[34] Yang R, Wang M, Zhang G, Bao Y, Wu Y, Li X, et al. E2F7-EZH2 axis regulates Pten/AKT/mTOR signalling and glioblastoma progression. British Journal of Cancer. 2020; 123: 1445–1455.

[35] Ashrafizadeh M, Zarrabi A, Samarghandian S, Najafi M. PTEN: what we know of the function and regulation of this oncosuppressor factor in bladder cancer? European Journal of Pharmacology. 2020; 881: 173226.

[36] Xi Z, Jing L, Le-Ni K, Zhu L, Ze-Wen D, Hui Y, et al. Evaluation of PTEN and CD4+FOXP3+ T cell expressions as diagnostic and predictive factors in endometrial cancer: A case control study. Medicine. 2019; 98: e16345.